Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

Clinical trial NCT06690827 · RECRUITING

Trial details

NCT number: NCT06690827
Sponsor: Chongqing Precision Biotech Co., Ltd
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

AML (Acute Myeloid Leukemia)BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)

Start date: 2024-11-13
Primary completion: 2027-10-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.